SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutic delivery, today announced the closing of its previously announced registered direct offering of an aggregate of 5,454,548 shares of the Company's common stock at an offering price of $1.10 per share of common stock and concurrent private placement of unregistered warrants to purchase up to 5,454,548 shares of common stock. The warrants have an exercise price of $1.10 per ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 67 Item 6. Reserved 67 Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations 68 Item 7A. Quantitative and Qualitative Disclosures About Market Risk 75 Item 8. Financial Statements and Supplementary Data 76 Item 9. Changes in and Disagreements With Accountants on Ac ...

Biora Therapeutics, Inc. (NASDAQ:BIOR) Q4 2023 Results Conference Call March 26, 2024 4:30 PM ET Company Participants Chuck Pedala - LifeSci Advisors Adi Mohanty - CEO Ariella Kelman - Chief Medical Officer Eric d'Esparbes - CFO Conference Call Participants John Vandermosten - Zacks Investment Research Operator Welcome to the Biora Therapeutics Fourth Quarter 2023 Financial Results Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow a formal presen ...

Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results Results demonstrated targeted drug delivery and absorption in the colon, with 3-4 times lower drug levels in blood SAN DIEGO, March 26, 2024 – Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today provided a corporate update and reported financial results for the fourth quarter and year ended December 31, 2023. Exhibit 99.1 All performance target ...

Monetization of legacy asset brings in $3 million in nondilutive capital Convertible notes exchange brings in another $2.8 million in new capital and reduces Biora's net debt SAN DIEGO, March 11, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutic delivery, today announced an agreement with institutional investor Context Capital to invest $2.8 million in new capital alongside a convertible note exchange, and announced the monetization of its ...

SAN DIEGO, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutic delivery, today announced it will participate in the Inflammatory Bowel Disease Symposium hosted virtually by Canaccord Genuity Capital Markets on Wednesday, February 28, 2024. Ariella Kelman, M.D., Chief Medical Officer, will participate in the panel titled "The Next Evolutionary Steps in Addressing IBD," beginning at 10:00 AM Eastern / 7:00 AM Pacific time. Interested pa ...

Biora Therapeutics, Inc. (NASDAQ:BIOR) Q3 2023 Earnings Conference Call November 13, 2023 4:30 PM ET Company Participants Chuck Pedala - LifeSci Advisors Adi Mohanty - CEO Eric d'Esparbes - CFO Conference Call Participants Joe Pantginis - H.C. Wainwright & Co. Julian Harrison - BTIG John Vandermosten - Zacks Investment Research Operator Greetings and welcome to the Biora Therapeutics Third Quarter 2023 earnings call. At this time, all participants are in a listen only mode. A brief question-and-answer sessi ...

Biora Therapeutics, Inc. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-39334 Delaware 27-3950390 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 4330 La Jolla Village Drive, Suite 300, San Diego, CA 92122 Registrant's telephone number, including a ...

Biora Therapeutics, Inc. (NASDAQ:BIOR) Q2 2023 Earnings Conference Call August 14, 2023 4:30 PM ET Company Participants Chuck Padala - Managing Director, LifeSci Advisors Adi Mohanty - Chief Executive Officer Eric d'Esparbes - Chief Financial Officer Conference Call Participants Joe Pantginis - H.C. Wainwright Julian Harrison - BTIG John Vandermosten - Zacks Investment Research Operator Greetings, and welcome to the Biora Therapeutics Second Quarter 2023 Earnings Call. At this time, all participants are in ...

Current and future legislation may increase the difficulty and cost for us, and any collaborators, to obtain marketing approval of and commercialize our drug candidates and affect the prices we, or they, may obtain. To date, there have been several recent U.S. congressional inquiries and proposed and enacted state and federal legislation and regulation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient support programs, ...